PAREXEL Launches Patient Sensor Solution to Transform Clinical Trial Data Collection
March 30 2017 - 9:00AM
Business Wire
Comprehensive wearables and sensors solution,
powered by the Perceptive MyTrials® Analytics platform, creates
greater efficiencies for biopharmaceutical companies
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced the
launch of its patient sensor solution, a new offering that securely
captures, transmits, stores, and visualizes study subject data in
clinical trials.
PAREXEL’s offering, powered by the Perceptive MyTrials®
Analytics platform, enables an end-to-end services and technology
solution that facilitates the remote collection of study subject
data via medical devices. Collection of clinical data via wearables
and sensors could replace or reduce the number of clinical
assessments and/or on-site visits during clinical trials. This
could potentially reduce the burden on trial participants and sites
as well as decrease trial costs. Wearable monitoring solutions also
allow data to be collected more often. Frequent collection of this
data can provide real-time meaningful insights into a study
subject’s behavior and health outside of visits, supporting better
compliance and real-time user feedback.
PAREXEL’s clinical trial expertise and the ability to collect
sensor-based data is designed to create efficiencies for sponsors,
eliminating the need to contract separately for wearable third
party devices to leverage sensors in a clinical study. According to
Frost and Sullivan, the global market for wearables in healthcare
is expected to reach $18.9 billion in 2020.1
“Due to evolving regulatory and payer standards in today’s
healthcare market, there is a growing need to leverage alternative
data sources in clinical trials. Wearables and sensors have the
potential to transform Phase I-IV trials as well as observational
studies. However, infrastructure and multi-functional expertise are
needed to validate the appropriate use of medical devices to
generate clinical and quality-of-life endpoints,” said Xavier
Flinois, President, PAREXEL Informatics. “PAREXEL’s offering could
disrupt the industry standard of collecting data during site visits
only, allowing biopharmaceutical sponsors to more easily
demonstrate safety and/or efficacy and differentiate treatments
from competition using remote monitoring approaches.”
The PAREXEL® patient sensor solution supports the generation of
real-world data that can demonstrate value beyond the data
collected during site visits. To deliver this solution, the Company
has partnered with technology providers, including OSIsoft, to
capture, securely transmit, store, and monitor data, as well as
generate alerts based on the potentially large volume of
time-series data from sensors.
The patient sensor solution is a complementary extension of
PAREXEL's current services, and is available through the Perceptive
MyTrials® platform. It is also available through the Company's
PAREXEL Partner Program. For more information, please visit:
https://www.parexel.com/solutions/informatics/patient-sensors.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology, and
medical device industries. Committed to providing solutions that
expedite time-to-market and peak-market penetration, PAREXEL has
developed significant expertise across the development and
commercialization continuum, from drug development and regulatory
consulting to clinical pharmacology, clinical trials management,
and reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 85 locations in 51 countries around the
world, and had approximately 19,625 employees in the second
quarter. For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL, PAREXEL Informatics and Perceptive MyTrials are
trademarks or registered trademarks of PAREXEL International
Corporation or its affiliates. All other trademarks are the
property of their respective owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
1 Wearable Technologies in Clinical and Consumer Health Report,
Frost & Sullivan, March 2016
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170330005102/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorJenny Radloff, PAN CommunicationsTel.: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1 781-434-4753Email: Ron.Aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Sep 2023 to Sep 2024